60

Dimethyl Fumarate 120mg and 240mg Gastro-Resistant Hard Capsule

Prescriber Criteria: Consultant Neurologist

Outpatient and Inpatient use:

1. Multiple Sclerosis

Reserved for the treatment of adult patients with relapsing remitting multiple sclerosis who have failed adequate therapeutic trials with a beta-interferon or teriflunomide for a minimum of 6 months.

Duration of Approval:

1 year initially
2 years thereafter